Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
0 patents granted to the name below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Inventiva S.A. American Depository Shares’s names, not what it holds today.
Patents granted
0
by type: not read, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
15
3 of them in 2025
Names they are printed under
1
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name1 counted
INVENTIVA its own name
named as the applicant on its applications, in FR
15 published
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Sep 18, 2025 | 2025/0290937 | Methods and monitoring of treatment with lanifibranor | Analysis of biological materials | INVENTIVA |
| Aug 21, 2025 | 2025/0263406 | DEUTERATED DERIVATIVES OF LANIFIBRANOR | Pharmaceuticals | INVENTIVA |
| Jul 31, 2025 | 2025/0243192 | CRYSTALLINE FORM OF LANIFIBRANOR | Organic fine chemistry | INVENTIVA |
| Dec 12, 2024 | 2024/0410904 | NON-INVASIVE MONITORING OF LIVER DISEASE TREATMENT | Pharmaceuticals | INVENTIVA |
| Dec 12, 2024 | 2024/0408069 | NON-INVASIVE MONITORING OF LIVER DISEASE TREATMENT | Analysis of biological materials | INVENTIVA |
| Jan 18, 2024 | 2024/0016807 | COMBINATION THERAPY FOR THE TREATMENT OF A LIVER DISEASE | Pharmaceuticals | INVENTIVA |
| Oct 21, 2021 | 2021/0323982 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | Organic fine chemistry | INVENTIVA · patent 11,999,758 granted from it |
| May 13, 2021 | 2021/0137937 | METHOD OF TREATMENT OF CIRRHOSIS | Pharmaceuticals | INVENTIVA · patent 11,504,380 granted from it |
| Apr 16, 2020 | 2020/0115353 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA | Organic fine chemistry | INVENTIVA |
| Nov 22, 2018 | 2018/0333396 | PPAR COMPOUNDS FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | Pharmaceuticals | INVENTIVA · patent 10,383,858 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 3 · Analysis of biological materials 2 · Organic fine chemistry 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.